EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan

Kazuya Takeda, Takaya Yamamoto, Rei Umezawa, Noriyoshi Takahashi, Shinsaku Okuda, Keiichi Jingu

Clinical Lung Cancer · 2026-07 · 27 (6) · 43-49

DOI: 10.1016/j.cllc.2026.05.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-07. Verfasst von Kazuya Takeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Radiation Oncology, South Miyag…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Chemoradiotherapy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalChemoradiotherapyAntineoplastic Agents, ImmunologicalHumansJapanAgedFemaleMaleDatabases, FactualAged, 80 and overMiddle AgedRadiation PneumonitisRetrospective Studies

Stichwörter der Autor:innen

ChemoradiotherapyImmune checkpoint inhibitorNon–small-cell lung cancerRadiation pneumonitisReal-world data

Substanzen

durvalumabAntibodies, MonoclonalAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Radiation Oncology, South Miyagi Medical Center, Shibata, Miyagi, Japan. Electronic address: kazuya.t…
  • Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Takeda, K., Yamamoto, T., Umezawa, R., Takahashi, N., Okuda, S., & Jingu, K. (2026). Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan. Clinical Lung Cancer, 27(6), 43-49. https://doi.org/10.1016/j.cllc.2026.05.010

Vancouver

Takeda K, Yamamoto T, Umezawa R, Takahashi N, Okuda S, Jingu K. Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan. Clinical Lung Cancer. 2026;27(6):43-49. doi:10.1016/j.cllc.2026.05.010

BibTeX
@article{Takeda2026,
  author = {Takeda, Kazuya and Yamamoto, Takaya and Umezawa, Rei and Takahashi, Noriyoshi and Okuda, Shinsaku and Jingu, Keiichi},
  title = {Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {43--49},
  doi = {10.1016/j.cllc.2026.05.010}
}
Kostenlos starten →